Hackman Jeffrey S. 4

What Happened

• Jeffrey S. Hackman, Chief Executive Officer of Fennec Pharmaceuticals (FENC), reported an acquisition on 2026-05-31 of 1,159 shares at $0.00 — these were shares released from restriction (not an open-market purchase or sale), reported on a Form 4 filed 2026-06-01. The filing shows acquisition value of $0 because these shares were previously awarded and are being released/vested.

Key Details

• Transaction date and price: 2026-05-31; 1,159 shares acquired at $0.00 per share.
• Filing date: 2026-06-01 (appears timely under Form 4 rules).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnote: F1 — "Represents shares released from restriction from shares awarded 3/28/2025."
• Transaction type: Award/Release of restricted stock (code A on Form 4).

Context

• This is a release/vesting of previously awarded restricted shares — a common form of executive compensation — rather than a new cash purchase or a sale. Such releases reflect scheduled compensation vesting and do not by themselves indicate buying or selling sentiment.